{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:14:57Z","timestamp":1740028497593,"version":"3.37.3"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1124\/jpet.119.264572","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:25:36Z","timestamp":1587774336000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["TAS-303 Ameliorates Carbachol-Induced Detrusor Overactivity in Rats, Revealing Its Therapeutic Potential for Overactive Bladder"],"prefix":"10.1016","volume":"374","author":[{"given":"Hiroya","family":"Mizutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukumitsu","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.264572_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrurol.2017.113","article-title":"Pharmacology: cardiovascular effects of mirabegron","volume":"14","author":"Andersson","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1124\/jpet.119.264572_bib5","first-page":"43","article-title":"Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology","volume":"175","author":"Andersson","year":"1995","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.1124\/jpet.119.264572_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejogrb.2015.02.020","article-title":"The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder","volume":"187","author":"Balachandran","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1124\/jpet.119.264572_bib7","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1523\/JNEUROSCI.22-18-08063.2002","article-title":"Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells","volume":"22","author":"Birder","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.119.264572_bib8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/00220345890680110401","article-title":"Vasoactive intestinal peptide interacts with alpha-adrenergic-, cholinergic-, and substance-P-mediated responses in rat parotid and submandibular glands","volume":"68","author":"Bobyock","year":"1989","journal-title":"J Dent Res"},{"key":"10.1124\/jpet.119.264572_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0031-6997(24)01425-X","article-title":"Adrenergic and muscarinic receptors in the human heart","volume":"51","author":"Brodde","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.119.264572_bib10","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.lfs.2007.01.053","article-title":"Expression and distribution of cholinergic receptors in the human urothelium","volume":"80","author":"Bschleipfer","year":"2007","journal-title":"Life Sci"},{"key":"10.1124\/jpet.119.264572_bib11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s12272-017-0988-9","article-title":"Inhibition of salivary secretion by tolterodine transdermal patch","volume":"40","author":"Byeon","year":"2017","journal-title":"Arch Pharm Res"},{"key":"10.1124\/jpet.119.264572_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"issue":"Suppl 3","key":"10.1124\/jpet.119.264572_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1464-410X.2009.08371.x","article-title":"The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS","volume":"103","author":"Coyne","year":"2009","journal-title":"BJU Int"},{"key":"10.1124\/jpet.119.264572_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2015.03.074","article-title":"Involvement of \u03b23-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor","volume":"758","author":"D\u2019 Agostino","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264572_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/nau.20208","article-title":"Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics","volume":"25","author":"De Laet","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib17","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/nau.23513","article-title":"The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States","volume":"37","author":"Durden","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib18","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1126\/science.2570461","article-title":"Molecular characterization of the human beta 3-adrenergic receptor","volume":"245","author":"Emorine","year":"1989","journal-title":"Science"},{"key":"10.1124\/jpet.119.264572_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0024-3205(93)90669-T","article-title":"Alterations in K(+)-evoked release of 3H-norepinephrine and contractile responses in urethral and bladder tissues induced by norepinephrine reuptake inhibition","volume":"53","author":"Foreman","year":"1993","journal-title":"Life Sci"},{"key":"10.1124\/jpet.119.264572_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00210-012-0814-3","article-title":"Effect of mirabegron, a novel \u03b23-adrenoceptor agonist, on bladder function during storage phase in rats","volume":"386","author":"Hatanaka","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.119.264572_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.eururo.2007.02.057","article-title":"Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve","volume":"52","author":"Iijima","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00210-002-0554-x","article-title":"M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland","volume":"366","author":"Ikeda","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.119.264572_bib25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/nau.23061","article-title":"Combined treatment with a \u03b23 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats","volume":"36","author":"Imamura","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM199602293340907","article-title":"Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors--evolving concepts and clinical implications","volume":"334","author":"Insel","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.119.264572_bib27","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib28","doi-asserted-by":"crossref","first-page":"744.e1","DOI":"10.1016\/j.urology.2011.08.080","article-title":"Pharmacological effect of TRK-380, a novel selective human \u03b23-adrenoceptor agonist, on mammalian detrusor strips","volume":"79","author":"Kanie","year":"2012","journal-title":"Urology"},{"key":"10.1124\/jpet.119.264572_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.urology.2004.11.021","article-title":"Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways","volume":"65","author":"Kim","year":"2005","journal-title":"Urology"},{"key":"10.1124\/jpet.119.264572_bib30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.eururo.2006.10.028","article-title":"Acetylcholine and molecular components of its synthesis and release machinery in the urothelium","volume":"51","author":"Lips","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2008.12.043","article-title":"Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist","volume":"605","author":"McNamara","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264572_bib33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.118.248039","article-title":"TAS-303, a novel selective norepinephrine reuptake inhibitor that increases urethral pressure in rats, indicating its potential as a therapeutic agent for stress urinary incontinence","volume":"366","author":"Mizutani","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264572_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.ju.0000067621.62736.7c","article-title":"A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders","volume":"170","author":"Nomiya","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/jpet.119.264572_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/luts.12007","article-title":"Expression of \u03b2-adrenoceptor subtypes in urothelium, interstitial cells and detrusor of the human urinary bladder","volume":"5","author":"Otsuka","year":"2013","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/jpet.119.264572_bib36","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/nau.23828","article-title":"Prevalence of lower urinary tract symptoms and overactive bladder in men and women over 18 years old: the Colombian overactive bladder and lower urinary tract symptoms (COBaLT) study","volume":"38","author":"Plata","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2710.2000.00292.x","article-title":"Management of urinary incontinence","volume":"25","author":"Sarkar","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/jpet.119.264572_bib39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.eururo.2013.06.043","article-title":"Protective effect of a \u03b23-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia","volume":"64","author":"Sawada","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.119.264572_bib40","doi-asserted-by":"crossref","first-page":"F388","DOI":"10.1152\/ajprenal.00392.2016","article-title":"Inhibition of cholinergic neurotransmission by \u03b23-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders","volume":"313","author":"Silva","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.119.264572_bib41","first-page":"3219","article-title":"beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current","volume":"118","author":"Skeberdis","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.119.264572_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2012.11.060","article-title":"The novel \u03b23-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity","volume":"699","author":"Sval\u00f8","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264572_bib43","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/01.ju.0000074622.50255.a8","article-title":"Functional characterization of beta-adrenoceptor subtypes in the canine and rat lower urinary tract","volume":"170","author":"Takeda","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/jpet.119.264572_bib44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/nau.10034","article-title":"Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats","volume":"21","author":"Takeda","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib45","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.juro.2006.06.088","article-title":"Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor","volume":"176","author":"Tyagi","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/jpet.119.264572_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2005.06.029","article-title":"Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors","volume":"518","author":"Uchida","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264572_bib47","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/nau.23066","article-title":"Combinational effects of muscarinic receptor inhibition and \u03b23-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury","volume":"36","author":"Wada","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.119.264572_bib48","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jash.2018.08.001","article-title":"Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome","volume":"12","author":"White","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"10.1124\/jpet.119.264572_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.108.142562","article-title":"Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man","volume":"328","author":"Wuest","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264572_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/iju.12008","article-title":"Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action","volume":"20","author":"Yamaguchi","year":"2013","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.119.264572_bib51","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1097\/01.ju.0000176793.50410.9e","article-title":"Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats","volume":"174","author":"Yokoyama","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/jpet.119.264572_bib52","doi-asserted-by":"crossref","unstructured":"Yono M, Kimura M, Inoue Y, Furukawa K, Ito K, Tsuruya K, Nagaoka M, Hoashi K, Irie S (2017) A double-blind, placebo-controlled clinical pharmacological study of TAS-303 in female patients with stress urinary incontinence, in Proceedings of ICS 2017; 2017 September 12\u201315; Florence, Italy, pp A382, The International Continence Society, Bristol, UK.","DOI":"10.26226\/morressier.59b63e41d462b80292389510"},{"key":"10.1124\/jpet.119.264572_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.urology.2005.08.014","article-title":"Non-neuronal cholinergic system in human bladder urothelium","volume":"67","author":"Yoshida","year":"2006","journal-title":"Urology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.264572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:54:51Z","timestamp":1739973291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0022356524257918"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.264572","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAS-303 Ameliorates Carbachol-Induced Detrusor Overactivity in Rats, Revealing Its Therapeutic Potential for Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.264572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}